Crenolanib
Phase 2Small molecule
Crenolanib is one of 176 small molecule programs targeting Glioma. It is currently in Phase 2.
5
Indications
18
Total Trials
0
Active Trials
175
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Lenograstim
SanofiPhase 3
Caspofungin Acetate
Merck & Co.Phase 3
Experimental
BiogenPhase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Oblimersen Sodium
NNational Cancer Institute (NCI)
Phase 3
Valspodar
EEastern Cooperative Oncology Group
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Sapacitabine
CCyclacel Pharmaceuticals, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia6 trials
Chemotherapy2 trials
Induction Chemotherapy1 trial
Diffuse Intrinsic Pontine Glioma1 trial
7 more indications
Treatment1 trial
Relapsed/Refractory AML1 trial
Gastric Adenocarcinoma1 trial
Hematologic Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Crenolanib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AArog Pharmaceuticals, Inc.